October 28, 2003Journal of Clinical Oncology
Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study
Authors
Discussion
Loading...
Member takes
Implication
Key Points
Key points are not available for this paper at this time.
Cite This Study
Coiffier et al. (2003) studied this question.